MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
批准号:
6350138
负责人:
RICHARD E HONKANEN
金额:
$23.85万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-01-01 至 2004-01-31
关键词:
MCF7 cell apoptosis biological signal transduction carcinogenesis cell growth regulation cell proliferation corticosteroid receptors enzyme activity enzyme mechanism expression cloning fluorescence microscopy gene induction /repression glucocorticoids hormone regulation /control mechanism immunocytochemistry immunofluorescence technique neoplastic cell northern blottings okadaic acid phosphatase inhibitor phosphoprotein phosphatase protein sequence transfection transforming growth factors tumor promoters
中文摘要
确定允许肿瘤细胞经历
不受控制的增殖对于理解致癌作用至关重要。
最近的一些研究表明,蛋白磷酸酶,如蛋白质
激酶,在细胞周期调控中发挥重要而特异的作用;
因此,这些蛋白质的表达或调节的改变可
影响细胞周期进程,甚至可以让细胞进行
不受控制的扩散。 蛋白磷酸酶在肿瘤中的作用
促进过程也出现在冈田酸的研究中,
微囊藻毒素-LR和calyculin A,三种高度特异性和有效的
某些丝氨酸/苏氨酸蛋白磷酸酶(PP酶)的抑制剂
具有促肿瘤活性。 我们克隆并鉴定了
三种人PPase,和一种命名为PP 5的PPase特别有吸引力,
进行进一步的研究。PP 5被冈田酸有效抑制,
calyculin A,小鼠皮肤中两种有效的肿瘤促进剂。 但不同于
其它已知的以恒定水平表达的PPase,PP 5
在对数生长期表达高,而在生长期低或检测不到。
静止或分化的细胞培养物。 PP 5的表达是
在某些细胞中加入血清和/或17 β-雌二醇诱导
PP 5表达的抑制增强了两者的能力,
p53肿瘤抑制蛋白和地塞米松,一种合成的
糖皮质激素激动剂,诱导p21细胞周期蛋白的表达,
依赖性激酶抑制剂蛋白。 综合这些
研究表明,PP 5在G1/S-调节中起重要作用。
相变 本提案旨在检验以下假设:
蛋白磷酸酶在细胞周期进程中起重要作用;
因此,干扰它们的活动可能有助于异常的
肿瘤细胞的增殖行为。 这些研究将重点
具体目标如下:目标1。 进一步描述角色
PP 5在细胞周期进程的正常和异常控制。
目的2.探讨PP 5在糖皮质激素介导的人肝癌细胞凋亡中的作用。
抑制细胞生长和信号网络之间的“串扰”
由激素和生长因子引起的。 目标3.描述
PP 5的表达调控机制。 通过这些研究,我们
希望进一步描述蛋白磷酸酶在
调节细胞周期,并深入了解蛋白质如何
磷酸酶可能参与肿瘤细胞的异常增殖,
细胞
英文摘要
Determining the mechanisms that allow neoplastic cells to undergo
uncontrolled proliferation is crucial to understanding carcinogenesis.
Several recent studies indicate that protein phosphatases, like protein
kinases, play important and specific roles in cell-cycle regulation;
thus alterations in the expression or regulation of these proteins may
affect cell-cycle progression and could even allow cells to undergo
unregulated proliferation. A role for protein phosphatases in the tumor
promotion process has also emerged from studies with okadaic acid,
microcystin-LR, and calyculin A, three highly specific and potent
inhibitors of certain serine/threonine protein phosphatases (PPases)
that have tumor promoting activity. We have cloned and characterized
three human PPases, and one, designated PP5, is particularly attractive
for further studies. PP5 is potently inhibited by okadaic acid and
calyculin A, two potent tumor promoters in mouse skin. However, unlike
the other known PPases, which are expressed at constant levels, PP5
expression is high during log phase growth and low or undetectable in
quiescent or differentiated cell cultures. The expression of PP5 is
induced by the addition of serum and/or 17beta-estradiol in some cell
types, and the inhibition of PP5 expression enhances the ability of both
the p53 tumor suppressor protein and dexamethasone, a synthetic
glucocorticoid agonist, to induce the expression of the p21 cyclin-
dependent kinase inhibitor protein in A549 cells. Together these
studies suggest that PP5 plays an important role in the regulation G1/S-
phase transition. This proposal is designed to test the hypothesis that
protein phosphatases play an important role in cell cycle progression;
thus, the interference of their activity may contribute to the aberrant
proliferative behavior of neoplastic cells. These studies will focus
on the following specific aims: Aim 1. Further characterize the roles
of PP5 in the normal and aberrant control of cell cycle progression.
Aim 2.Characterize the relationship of PP5 in glucocorticoid mediated
inhibition of cell growth and "cross talk" between signaling networks
induced by hormones and growth factors. Aim 3.Characterize the
mechanisms regulating the expression of PP5. Through these studies we
hope to further characterize the role of protein phosphatases in the
regulation of cell cycle and gain insight into the how protein
phosphatases may be involved in the aberrant proliferation of neoplastic
cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8337404
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8668135
-
项目类别:
-
资助金额:$33.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8181189
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Methods to enable cholesterol catabolism in human monocyte derived macrophages
-
批准号:8496113
-
项目类别:
-
资助金额:$32.41万
-
财政年份:2011
-
负责人:RICHARD E HONKANEN
-
依托单位:
Development of a HTS-assay for inhibitors of a type 2C protein phosphatase (PPM
-
批准号:7993354
-
项目类别:
-
资助金额:$14.83万
-
财政年份:2010
-
负责人:RICHARD E HONKANEN
-
依托单位:
HTP screening for inhibitors of ser/the protein phosphatase 5
-
批准号:7694097
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2009
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6183372
-
项目类别:
-
资助金额:$20.6万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6389765
-
项目类别:
-
资助金额:$21.21万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:6527128
-
项目类别:
-
资助金额:$21.85万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
CARDIOPROTECTIVE AGENTS IN ISCHEMIC MYOCYTES
-
批准号:2752396
-
项目类别:
-
资助金额:$19.36万
-
财政年份:1999
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2843978
-
项目类别:
-
资助金额:$24.48万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7030965
-
项目类别:
-
资助金额:$25.66万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7921141
-
项目类别:
-
资助金额:$2.5万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7027545
-
项目类别:
-
资助金额:$5.1万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:6872168
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101510
-
项目类别:
-
资助金额:$10.83万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101512
-
项目类别:
-
资助金额:$9.86万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:6774616
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
Mechanisms of tumor promotion and carcinogenesis
-
批准号:7209837
-
项目类别:
-
资助金额:$24.92万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
MECHANISMS OF TUMOR PROMOTION AND CARCINOGENESIS
-
批准号:2101511
-
项目类别:
-
资助金额:$8.75万
-
财政年份:1994
-
负责人:RICHARD E HONKANEN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: